Credit Suisse Ag Nkarta, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$5.14 - $14.35 $117,556 - $328,198	22,871 Added 12497.81%	23,054 $138,000
Q3 2022 Nov 10, 2022	BUY	$12.27 - $18.39 $1,950 - $2,924	159 Added 662.5%	183 $2,000
Q2 2022 Aug 12, 2022	BUY	$7.77 - $19.44 $186 - $466	24 New	24 $0
Q2 2021 Aug 16, 2021	SELL	$23.94 - $36.68 $159,655 - $244,618	-6,669 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$31.33 - $59.61 $193,400 - $367,972	-6,173 Reduced 48.07%	6,669 $219,000
Q4 2020 Feb 12, 2021	BUY	$27.03 - $75.62 $347,119 - $971,112	12,842 New	12,842 $789,000

129

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $119M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.